Logo image of ALGAE.PA

FERMENTALG (ALGAE.PA) Stock Fundamental Analysis

EPA:ALGAE - Euronext Paris - Matif - FR0011271600 - Common Stock - Currency: EUR

0.577  +0.07 (+14.03%)

Fundamental Rating

3

Overall ALGAE gets a fundamental rating of 3 out of 10. We evaluated ALGAE against 61 industry peers in the Chemicals industry. While ALGAE seems to be doing ok healthwise, there are quite some concerns on its profitability. ALGAE is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ALGAE had negative earnings in the past year.
In the past year ALGAE has reported a negative cash flow from operations.
In the past 5 years ALGAE always reported negative net income.
In the past 5 years ALGAE always reported negative operating cash flow.
ALGAE.PA Yearly Net Income VS EBIT VS OCF VS FCFALGAE.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

The Return On Assets of ALGAE (-25.27%) is worse than 83.61% of its industry peers.
Looking at the Return On Equity, with a value of -39.31%, ALGAE is doing worse than 75.41% of the companies in the same industry.
Industry RankSector Rank
ROA -25.27%
ROE -39.31%
ROIC N/A
ROA(3y)-23.57%
ROA(5y)-19.68%
ROE(3y)-36.06%
ROE(5y)-31.33%
ROIC(3y)N/A
ROIC(5y)N/A
ALGAE.PA Yearly ROA, ROE, ROICALGAE.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Gross Margin of ALGAE (21.70%) is worse than 62.30% of its industry peers.
In the last couple of years the Gross Margin of ALGAE has declined.
ALGAE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 21.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.82%
GM growth 5YN/A
ALGAE.PA Yearly Profit, Operating, Gross MarginsALGAE.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

4

2. Health

2.1 Basic Checks

ALGAE does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALGAE has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ALGAE has more shares outstanding
The debt/assets ratio for ALGAE has been reduced compared to a year ago.
ALGAE.PA Yearly Shares OutstandingALGAE.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ALGAE.PA Yearly Total Debt VS Total AssetsALGAE.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

ALGAE has an Altman-Z score of 1.38. This is a bad value and indicates that ALGAE is not financially healthy and even has some risk of bankruptcy.
ALGAE has a Altman-Z score of 1.38. This is in the lower half of the industry: ALGAE underperforms 72.13% of its industry peers.
ALGAE has a Debt/Equity ratio of 0.21. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.21, ALGAE is doing good in the industry, outperforming 75.41% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Altman-Z 1.38
ROIC/WACCN/A
WACC6.32%
ALGAE.PA Yearly LT Debt VS Equity VS FCFALGAE.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M 40M

2.3 Liquidity

ALGAE has a Current Ratio of 2.53. This indicates that ALGAE is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 2.53, ALGAE is doing good in the industry, outperforming 75.41% of the companies in the same industry.
ALGAE has a Quick Ratio of 2.43. This indicates that ALGAE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.43, ALGAE belongs to the top of the industry, outperforming 88.52% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.53
Quick Ratio 2.43
ALGAE.PA Yearly Current Assets VS Current LiabilitesALGAE.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 46.10% over the past year.
Looking at the last year, ALGAE shows a very strong growth in Revenue. The Revenue has grown by 183.32%.
The Revenue has been growing by 43.52% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)46.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.55%
Revenue 1Y (TTM)183.32%
Revenue growth 3Y26.74%
Revenue growth 5Y43.52%
Sales Q2Q%201.4%

3.2 Future

ALGAE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.96% yearly.
Based on estimates for the next years, ALGAE will show a very strong growth in Revenue. The Revenue will grow by 39.99% on average per year.
EPS Next Y38.46%
EPS Next 2Y24.03%
EPS Next 3Y22.68%
EPS Next 5Y17.96%
Revenue Next Year41.74%
Revenue Next 2Y47.44%
Revenue Next 3Y54.36%
Revenue Next 5Y39.99%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
ALGAE.PA Yearly Revenue VS EstimatesALGAE.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20M 40M 60M 80M 100M
ALGAE.PA Yearly EPS VS EstimatesALGAE.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -0.2 -0.4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ALGAE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALGAE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALGAE.PA Price Earnings VS Forward Price EarningsALGAE.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALGAE.PA Per share dataALGAE.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 0.3

4.3 Compensation for Growth

A more expensive valuation may be justified as ALGAE's earnings are expected to grow with 22.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.03%
EPS Next 3Y22.68%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALGAE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FERMENTALG

EPA:ALGAE (5/8/2025, 7:00:00 PM)

0.577

+0.07 (+14.03%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)04-02 2025-04-02
Earnings (Next)07-08 2025-07-08
Inst Owners25.99%
Inst Owner ChangeN/A
Ins Owners2.11%
Ins Owner ChangeN/A
Market Cap49.72M
Analysts84.44
Price Target0.61 (5.72%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)12.15%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-14.29%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.32
P/FCF N/A
P/OCF N/A
P/B 1.52
P/tB 2.78
EV/EBITDA N/A
EPS(TTM)-0.17
EYN/A
EPS(NY)-0.08
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0.13
BVpS0.38
TBVpS0.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.27%
ROE -39.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 21.7%
FCFM N/A
ROA(3y)-23.57%
ROA(5y)-19.68%
ROE(3y)-36.06%
ROE(5y)-31.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.82%
GM growth 5YN/A
F-Score5
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25.36%
Cap/Sales 5.63%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.53
Quick Ratio 2.43
Altman-Z 1.38
F-Score5
WACC6.32%
ROIC/WACCN/A
Cap/Depr(3y)32.24%
Cap/Depr(5y)108.18%
Cap/Sales(3y)12.02%
Cap/Sales(5y)34.66%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.55%
EPS Next Y38.46%
EPS Next 2Y24.03%
EPS Next 3Y22.68%
EPS Next 5Y17.96%
Revenue 1Y (TTM)183.32%
Revenue growth 3Y26.74%
Revenue growth 5Y43.52%
Sales Q2Q%201.4%
Revenue Next Year41.74%
Revenue Next 2Y47.44%
Revenue Next 3Y54.36%
Revenue Next 5Y39.99%
EBIT growth 1Y19.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year62.75%
EBIT Next 3Y29.01%
EBIT Next 5Y22.54%
FCF growth 1Y87.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y93.88%
OCF growth 3YN/A
OCF growth 5YN/A